We were proud to see the DCVMN Pharmacovigilance Working Group represented at the International Society of Pharmacovigilance (ISoP) 2025 Annual Meeting in Cairo on 24-27 October. Ms. Maria Beatriz Lucchesi attended on behalf of the Working Group to share the perspectives and key findings from the group’s recent work on strengthening vaccine safety surveillance in low- and middle-income countries. The ISoP meeting provided a timely forum to discuss how pharmacovigilance systems must adapt and innovate as vaccine deployment and technologies evolve.
Earlier this year, the PV Working Group published the peer-reviewed paper “Active vaccine safety surveillance in low- and middle-income countries: Challenges for vaccine manufacturers from emerging countries.” The publication aimed to strengthen understanding of active vaccine safety surveillance (AVSS) and its practical tools, while identifying the support needs, opportunities, challenges, and barriers manufacturers face in implementing AVSS in low- and middle-income countries. Drawing on insights from DCVMN members, the paper also proposes concrete solutions to help overcome these challenges and enhance the implementation of AVSS across diverse country contexts, a key step toward ensuring stronger, data-driven vaccine safety monitoring globally.
The participation of the Pharmacovigilance Working Group at ISoP 2025 underscores DCVMN’s continued commitment to advancing vaccine safety and ensuring that the voices and experiences of manufacturers from developing countries are represented in global pharmacovigilance dialogues!
📖 Read the full publication here: https://www.sciencedirect.com/science/article/abs/pii/S0264410X25000246?via%3Dihub
